These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30841473)

  • 1. Repositioning of fluoroquinolones from antibiotic to anti-cancer agents: An underestimated truth.
    Yadav V; Talwar P
    Biomed Pharmacother; 2019 Mar; 111():934-946. PubMed ID: 30841473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Development of Fluoroquinolone Derivatives as Anticancer Agents.
    Nowakowska J; Radomska D; Czarnomysy R; Marciniec K
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive review of the repositioning of non-oncologic drugs for cancer immunotherapy.
    Rauf A; Joshi PB; Olatunde A; Hafeez N; Ahmad Z; Hemeg HA; Aljohani ASM; Al Abdulmonem W; Thiruvengadam M; Viswanathan D; Rajakumar G; Thiruvengadam R
    Med Oncol; 2024 Apr; 41(5):122. PubMed ID: 38652344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revisiting Non-Cancer Drugs for Cancer Therapy.
    Yang EJ; Wu C; Liu Y; Lv J; Sup Shim J
    Curr Top Med Chem; 2016; 16(19):2144-55. PubMed ID: 26881712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The newer fluoroquinolones.
    Bolon MK
    Infect Dis Clin North Am; 2009 Dec; 23(4):1027-51, x. PubMed ID: 19909896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insight view on possible role of fluoroquinolones in cancer therapy.
    Sharma PC; Chaudhary M; Sharma A; Piplani M; Rajak H; Prakash O
    Curr Top Med Chem; 2013 Aug; 13(16):2076-96. PubMed ID: 23895089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New fluoroquinolones: levofloxacin, moxifloxacin and gatifloxacin].
    Hoepelman I
    Ned Tijdschr Geneeskd; 2004 Oct; 148(43):2115-21. PubMed ID: 15553354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathway-Based Drug Repositioning for Cancers: Computational Prediction and Experimental Validation.
    Iwata M; Hirose L; Kohara H; Liao J; Sawada R; Akiyoshi S; Tani K; Yamanishi Y
    J Med Chem; 2018 Nov; 61(21):9583-9595. PubMed ID: 30371064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing old drugs to fight multidrug resistant cancers.
    Dinić J; Efferth T; García-Sosa AT; Grahovac J; Padrón JM; Pajeva I; Rizzolio F; Saponara S; Spengler G; Tsakovska I
    Drug Resist Updat; 2020 Sep; 52():100713. PubMed ID: 32615525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing psychiatric drugs as anti-cancer agents.
    Huang J; Zhao D; Liu Z; Liu F
    Cancer Lett; 2018 Apr; 419():257-265. PubMed ID: 29414306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Repurposing in Anticancer Reagent Development.
    Chen PC; Liu X; Lin Y
    Comb Chem High Throughput Screen; 2017; 20(5):395-402. PubMed ID: 28025934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action?
    Dalhoff A
    Eur J Clin Microbiol Infect Dis; 2015 Apr; 34(4):661-8. PubMed ID: 25515946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Oncology Drug Repositioning and Polypharmacology.
    Cheng F
    Methods Mol Biol; 2019; 1878():243-261. PubMed ID: 30378081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets.
    Mudduluru G; Walther W; Kobelt D; Dahlmann M; Treese C; Assaraf YG; Stein U
    Drug Resist Updat; 2016 May; 26():10-27. PubMed ID: 27180307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluoroquinolones: Non-antibacterial properties].
    Leyva-Ramos S; Hernández-López H
    Rev Esp Quimioter; 2017 Feb; 30(1):1-8. PubMed ID: 27976571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systems biology based drug repositioning for development of cancer therapy.
    Turanli B; Altay O; Borén J; Turkez H; Nielsen J; Uhlen M; Arga KY; Mardinoglu A
    Semin Cancer Biol; 2021 Jan; 68():47-58. PubMed ID: 31568815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based drug repositioning: Potential and limits.
    Adasme MF; Parisi D; Sveshnikova A; Schroeder M
    Semin Cancer Biol; 2021 Jan; 68():192-198. PubMed ID: 32032699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repositioning of proton pump inhibitors in cancer therapy.
    Lu ZN; Tian B; Guo XL
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):925-937. PubMed ID: 28861639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of fluoroquinolone use to avoid microbial resistance in clinical practice.
    Peterson LR
    Postgrad Med; 2001 Feb; 109(2 Suppl):51-9. PubMed ID: 19667558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology of the fluoroquinolones: a perspective for the use in domestic animals.
    Martinez M; McDermott P; Walker R
    Vet J; 2006 Jul; 172(1):10-28. PubMed ID: 16154368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.